Exhibit 10.7
Form 10-KSB, 2001
Viral Genetics, Inc.
File No. 000-26875

Viral Genetics, Inc.

                                                      905 Mission Avenue
                                                      South Pasadena,
                                                      California 91030
                                                      Telephone 323-682-2172
                                                      Facsimile 626-799-2265


To:   Phillip C. Baker
      Baker Consulting

From: Viral Genetics, Inc.

Date: May 23, 2000


Re:   Letter Agreement



            This letter Agreement is given with reference to the following:

     1.   Viral entered into an agreement with Americredit  National Corporation
          which,  by it terms,  was set to expire on May 12, 2000 unless certain
          conditions were met by Americredit. Americredit was unable to meet its
          obligations  by the date  specified  under the  agreement  and  Viral,
          accordingly,  terminated the agreement by letter to Americredit  dated
          May 13, 2000.

     2.   Baker now desires to enter into a  non-exclusive  agreement with Viral
          respecting the business of Viral as hereinafter set forth.

     3.   Baker represents to Viral it has the legal and financial capability to
          obtain the sale of capital stock of Viral of not less than $61,000,000
          within 24 days of the execution of this agreement by Viral pursuant to
          a private  placement in  accordance  with all  applicable  federal and
          state  securities  law. In exchange  therefore and upon receipt of the
          $61,000,000 by Viral, Viral shall issue to those investors  comprising
          the private placement not less than 21% of the total outstanding stock
          of Viral on the date of issue as set forth in the  private  placement.
          Baker  represents it has the experience and expertise to determine the
          fair market value for Viral and,  for the purposes of this  agreement,
          has  placed  an  initial  total  value  of  Viral  at  not  less  than
          $300,000,000.

                                      E-51
<PAGE>

     4.   In consideration of Viral allowing Baker the Opportunity to enter into
          this  non-exclusive  agreement for the purposes set forth above, Baker
          shall deliver to Viral,  no later than June 2, 2000, a cashier's check
          or wire transfer in the amount of $1,000,000 made payable to Viral and
          drawn on a commercially acceptable banking institution. Provided Viral
          receives the funds  mentioned in Articles 3 above in  accordance  with
          the  provisions  therein,  Viral shall issue to the person  giving the
          $1,000,000 one percent of the total outstanding  shares of Viral as of
          the date of execution by Viral of this agreement.

     5.   Baker shall receive a fee of 10% in the event  $60,000,000 is received
          by Viral pursuant to the private placement mentioned above.

     6.   Provided Viral has received the $1,000,000 from Baker mentioned above,
          the term of this non-exclusive  agreement shall be for a period not to
          exceed 6 months  from its  execution  by  Viral.  In the  event  Viral
          receives the funds mentioned in Article 3 above in accordance with the
          provisions  therein,  this  agreement  shall be exclusive and its term
          shall be for a period not to exceed 24 months  from its  execution  by
          Viral.

     7.   Baker shall receive a fee to be mutually  agreed for any future public
          offering of the stock of Viral funded by Baker during the term of this
          agreement.

     8.   Baker may not assign this agreement  without the prior written consent
          of Viral.

     9.   This agreement when signed below by the indicated  representatives  of
          the parties hereto  constitutes  the entire  agreement of the parties;
          supersedes all other  agreements;  and may only be amended or modified
          by a writing signed by both parties.

     10.  The  persons   executing  this  agreement  hereby  represent  each  is
          authorized to enter into this  agreement on behalf of the corporate or
          other entity a party hereto.

     11.  Any notice  required or permitted to be given under this  agreement by
          one party to the other shall be in writing.

     12.  This  agreement  shall  be  governed  by  the  laws  of the  State  of
          California.



         AGREED:                                      VIRAL GENETICS, INC.


         BAKER CONSULTING:



         /s/ Phillip C. Baker                         /s/ Haig Keledjian

                                      E-52
<PAGE>

                                    Addendum


     Addendum to a contract  dated May 23, 2000  Section 5 in replace to read as
follows:

     Baker  shall  receive  a fee of 10%  cash  and  1.5%  stock,  of the  total
outstanding  shares of viral, in the event that $60,000,000 is received by Viral
Genetics pursuant to the private placement mentioned above. The 1.5% stock shall
be issued to Baker Consulting after completion of the placement and at the final
transaction.  Which will equate to 1.5% of the total  outstanding  shares of VG,
simultaneously after the $60,000,000 or private placement is completed.


/s/ Phillip C. Baker                                        /s/ Haig Kelledjian

                                      E-53
<PAGE>



1630 north main St #234 Walnut Creek, CA 94596
Tel  (916) 776-1167
Fax (916) 776-1168                                              Baker Consulting


Fax

To:   Haig Kelledjian                           From: Phil Baker
------------------------------------------------------------------------------

Fax:  626-799-2265                              Pages:      1
------------------------------------------------------------------------------

Phone:      323-682-2172                        Date: 6/25/00
------------------------------------------------------------------------------

Re:   Extension                                 CC:   Mr. Russell Ratliffe
------------------------------------------------------------------------------

  Urgent    For Review      Please Comment     Please Reply     Please Recycle

------------------------------------------------------------------------------

o  Comments:

Dear Haig and Hampar:

Baker  Consulting is  requesting  an extension of the original  agreement set to
expire on June 28th.  This  extension is based upon a  continuing  non-exclusive
agreement that will expire on July 28th, 2000.

Baker  Consulting  along with Mr.  Russell  Ratliffe are  aggressively  pursuing
multiple  sources of funding for Viral Genetics.  These efforts have resulted in
locating  several new  sources of funds as well as  continuing  to consider  the
groups represented by Lucien Verget and Chris Johnson.

This agreement would have the same terms based upon a successful closing for the
$61 million  investment  amount to purchase the agreed upon  percentage of Viral
Genetics  with the same  commission  schedules and  arrangements.  Upon a formal
receipt of a letter of commitment  from any of the  acceptable  funding  sources
this agreement  would then become an exclusive  agreement  based upon receipt of
the bridge financing of $1 million prior to closing of the full amount.

If you agree to this extension  please sign this fax letter and return a copy of
the signed letter.

Sincerely

      Phillip C. Baker / President Baker Consulting

Viral Genetics Inc.     /s/ Haig Keledjian                  Date 6/25/00

Baker Consulting        /s/ Phillip C. Baker                Date______

Mr. Russell Ratliffe    /s/ Russell Ratliffe                Date______


                                      E-54